EVL.BE - Evolus Inc
| Previous close | 8.35 |
| Open | 8.35 |
| Bid | 8.30 x 0 |
| Ask | 8.80 x 0 |
| Day's range | 8.35 - 8.55 |
| 52-week range | 6.15 - 13.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 July 2023 - 04 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Evolus (NASDAQ:EOLS) rallies 16% this week, taking three-year gains to 161%
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
ZacksEvolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireEvolus Reports First Quarter 2023 Results and Provides Business Update
NEWPORT BEACH, Calif., May 09, 2023--Evolus, Inc. reports financial results for the first quarter ended March 31, 2023 and provides a business update.
Business WireEvolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
NEWPORT BEACH, Calif., May 09, 2023--Evolus, Inc. announces it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers.
Business WireEvolus to Report First Quarter 2023 Results and Provide Business Update
NEWPORT BEACH, Calif., May 05, 2023--Evolus, Inc. announces that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023.
- Simply Wall St.
Evolus, Inc.'s (NASDAQ:EOLS) P/S Still Appears To Be Reasonable
It's not a stretch to say that Evolus, Inc.'s ( NASDAQ:EOLS ) price-to-sales (or "P/S") ratio of 3.2x right now seems...
ZacksEvolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireEvolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
NEWPORT BEACH, Calif., March 08, 2023--Evolus reports financial results for the fourth quarter and full year ended December 31, 2022 and provides a business update
Business WireEvolus to Participate in the Barclays Global Healthcare Conference
NEWPORT BEACH, Calif., February 28, 2023--Evolus announces that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida.
Business WireEvolus Initiates Nuceiva® Launch in Germany and Austria
NEWPORT BEACH, Calif., February 27, 2023--Evolus commences the commercial launch of Nuceiva® in Germany and Austria, and is now available for direct order and delivery to customers.
Business WireEvolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
NEWPORT BEACH, Calif., February 22, 2023--Evolus announces that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023.
Business WireEvolus Not Affected by Recent Korean Court Ruling
NEWPORT BEACH, Calif., February 10, 2023--Evolus issues the following statement.
Business WireEvolus to Participate in the SVB Securities Global Biopharma Conference
NEWPORT BEACH, Calif., January 31, 2023--Evolus announces that members of its management team will be participating in the SVB Securities Global Biopharma Conference.
- Simply Wall St.
Institutional investors own a significant stake of 39% in Evolus, Inc. (NASDAQ:EOLS)
To get a sense of who is truly in control of Evolus, Inc. ( NASDAQ:EOLS ), it is important to understand the ownership...
Business Wire"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
NEWPORT BEACH, Calif., January 28, 2023--Evolus presents interim data from its Phase II clinical study at the 2023 IMCAS World Congress in Paris.
Business WireEvolus Receives Regulatory Approval for Nuceiva® in Australia
NEWPORT BEACH, Calif., January 23, 2023--Evolus announces that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva®.
Business WireEvolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress
NEWPORT BEACH, Calif., January 23, 2023--Evolus will present interim findings from a Phase 2 study for its "extra-strength" dose of Jeuveau® at the 2023 IMCAS World Congress.
Motley FoolWhy Evolus Shares Jumped This Week
Shares of Evolus (NASDAQ: EOLS) were up by 27.1% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The medical aesthetics company specializes in using neurotoxins as aesthetic therapies. The company said in its announcement that it expected fourth-quarter revenue of $43.6 million, up 26% year over year, and full-year revenue of $148.6 million, up 49% over 2021.
Business WireEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
NEWPORT BEACH, Calif., January 18, 2023--Evolus announces its preliminary, unaudited net revenue as of and for the fourth quarter and full-year ended December 31, 2022.
- Simply Wall St.
Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit
Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...
Business WireEvolus Extends Term of Credit Facility with Pharmakon Advisors
NEWPORT BEACH, Calif., December 08, 2022--Evolus announces it has extended the expiration date of the second undrawn tranche under its existing term loan financing facility.
PR NewswireLeading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.
Pipeline Medical, a MedTech marketplace focused on supplying pharmaceuticals and medical supplies to medical professionals around the country, recently announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus, Inc. (NASDAQ: EOLS).
- Simply Wall St.
Shareholders in Evolus (NASDAQ:EOLS) are in the red if they invested three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Simply Wall St.
Evolus Third Quarter 2022 Earnings: Revenues Disappoint
Evolus ( NASDAQ:EOLS ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.9m (up 27% from 3Q 2021). Net...
ZacksEvolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
